LON:GSK GSK (GSK) Share Price, News & Analysis → They said crypto was dead. It went up 100X. (From InvestorPlace) (Ad) Free GSK Stock Alerts GBX 1,660.80 +11.20 (+0.68%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range 1,644.80▼ 1,663.4050-Day Range 1,521.20▼ 1,711.2052-Week Range 1,302.60▼ 1,719.80Volume4.17 million shsAverage Volume7.61 million shsMarket Capitalization£67.43 billionP/E Ratio1,384.00Dividend Yield3.85%Price TargetGBX 1,658.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability Get GSK alerts: Email Address GSK MarketRank™ Stock AnalysisAnalyst RatingHold2.43 Rating ScoreUpside/Downside0.1% DownsideGBX 1,658.75 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainability-1.56Upright™ Environmental ScoreNews Sentiment-0.17Based on 6 Articles This WeekInsider TradingSelling Shares£231.78 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.91 out of 5 stars 1.2 Analyst's Opinion Consensus RatingGSK has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 1,658.75, GSK has a forecasted downside of 0.1% from its current price of GBX 1,660.80.Amount of Analyst CoverageGSK has only been the subject of 4 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GSK. Previous Next 1.7 Dividend Strength Dividend LeadershipGSK is a leading dividend payer. It pays a dividend yield of 3.83%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthGSK does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of GSK is 5,333.33%. Payout ratios above 75% are not desirable because they may not be sustainable. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGSK has received a 66.82% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "HIV medication", "Shingles vaccines", "Mouthwash", "Clinical research services for infectious diseases", "Clinical research services for cancer", and "Clinical research services for the respiratory system" products. See details.Environmental SustainabilityThe Environmental Impact score for GSK is -1.56. Previous Next 2.1 News and Social Media Coverage News SentimentGSK has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for GSK this week, compared to 7 articles on an average week.Search Interest67 people have searched for GSK on MarketBeat in the last 30 days. This is an increase of 49% compared to the previous 30 days.MarketBeat Follows7 people have added GSK to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GSK insiders have sold 639.24% more of their company's stock than they have bought. Specifically, they have bought £313,532.76 in company stock and sold £2,317,751.36 in company stock.Percentage Held by InsidersOnly 2.25% of the stock of GSK is held by insiders.Percentage Held by Institutions45.49% of the stock of GSK is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of GSK is 1,384.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 149.72.Price to Earnings Ratio vs. SectorThe P/E ratio of GSK is 1,384.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 206.39.Price to Earnings Growth RatioGSK has a PEG Ratio of 1.29. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGSK has a P/B Ratio of 5.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Bull ReportThe AI Bottleneck No One is Talking AboutRenewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.Click here to see who's preparing to meet these needs About GSK Stock (LON:GSK)GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.Read More GSK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GSK Stock News HeadlinesMarch 18, 2024 | msn.comGSK Reveals New Phase 3 Data For Jemperli Combo Therapy To Support Expanded Use Approval For Wider Endometrial CancerMarch 18, 2024 | lse.co.ukGSK says Jemperli combination gets good results for endometrial cancerMarch 19, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… March 18, 2024 | marketwatch.comGSK's Endometrial Cancer Treatment Study Shows Combination PotentialMarch 13, 2024 | americanbankingnews.comGSK (LON:GSK) Receives Buy Rating from Deutsche Bank AktiengesellschaftMarch 9, 2024 | finance.yahoo.comGSK Mar 2024 41.000 callMarch 9, 2024 | finance.yahoo.comGSK Mar 2024 34.000 putMarch 9, 2024 | americanbankingnews.comGSK (LON:GSK) Stock Rating Reaffirmed by Shore CapitalMarch 19, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 7, 2024 | msn.comGSK's Withdrawn Multiple Myeloma Drug Shows Encouraging Combination Therapy Data In Second Late-Stage StudyMarch 7, 2024 | msn.comGSK’s Blenrep combo therapy meets key goal in multiple myeloma trialMarch 7, 2024 | msn.comGSK's blood cancer drug meets main goal in late-stage trial; analysts tout comebackMarch 6, 2024 | es-us.finanzas.yahoo.comCORRECTED-GSK's new HIV drug formula could support longer dosing intervals (March 4)March 6, 2024 | msn.comWHO warns of growing resistance to GSK's HIV drugMarch 4, 2024 | msn.comNew HIV drug Cabotegravir that can be taken as little as three times a year boosts GSKMarch 4, 2024 | investing.comGuggenheim lifts GSK to Buy on improved growth outlookMarch 4, 2024 | theglobeandmail.comHow DEI is helping GSK get ahead of diseaseMarch 1, 2024 | theguardian.comGSK boss’s annual pay package jumps 50% to £12.7mFebruary 26, 2024 | finance.yahoo.comGSK drug meets goal in late-stage gonorrhea studyFebruary 26, 2024 | msn.comGSK's Gepotidacin Oral Antibiotic Non-Inferior To Commonly Used Muscle-Injected Antibiotic Combo For Sexually Transmitted InfectionFebruary 26, 2024 | thetimes.co.ukGSK’s new gonorrhoea pill ‘as good as injected antibiotic’February 26, 2024 | msn.comGSK’s gonorrhoea drug achieves efficacy goal in pivotal trialFebruary 24, 2024 | msn.comGSK (GLAXF) Price Target Increased by 9.32% to 24.05February 21, 2024 | msn.comGSK reports robust results from latest trial with injectable HIV treatmentFebruary 20, 2024 | msn.comDespite being around an 18-month high, GSK’s share price looks cheap to meFebruary 20, 2024 | msn.comGSK’s Julie Brown to join drinks giant Diageo’s boardFebruary 17, 2024 | ca.finance.yahoo.comFour Days Left Until GSK plc (LON:GSK) Trades Ex-DividendSee More Headlines Receive GSK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/29/2020Ex-Dividend for 1/11 Dividend11/16/2023Dividend Payable1/11/2024Ex-Dividend for 4/11 Dividend2/22/2024Today3/19/2024Dividend Payable4/11/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolLON:GSK CUSIPN/A CIKN/A Webwww.gsk.com Phone+44-20-80475000FaxN/AEmployees70,212Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 1,658.75 High Stock Price TargetGBX 1,950 Low Stock Price TargetGBX 1,300 Potential Upside/Downside-0.1%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 1.20 Trailing P/E Ratio1,384.00 Forward P/E Ratio10.59 P/E Growth1.29Net Income£4.93 billion Net Margins16.25% Pretax MarginN/A Return on Equity46.38% Return on Assets8.81% Debt Debt-to-Equity Ratio140.82 Current Ratio0.88 Quick Ratio0.73 Sales & Book Value Annual Sales£30.33 billion Price / Sales2.22 Cash FlowGBX 203.89 per share Price / Cash Flow8.15 Book ValueGBX 329 per share Price / Book5.05Miscellaneous Outstanding Shares4,060,000,000Free FloatN/AMarket Cap£67.43 billion OptionableNot Optionable Beta0.26 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMs. Emma Natasha Walmsley (Age 55)CEO & Director Comp: $5.39MMs. Julie Belita Brown (Age 62)CFO & Executive Director Comp: $5.14MMs. Shobie Ramakrishnan (Age 53)Chief Digital & Technology Officer Mr. Tony WoodChief Scientific Officer and Head of R&DMs. Sarah Elton-FarrHead of Investor RelationsMr. James FordSenior VP & Group General Counsel of Legal & ComplianceMs. Sally JacksonSenior Vice President of Global Communications & CEO OfficeMr. David Simon Redfern BSc (Hons) (Age 58)CA, President of Corporate Development Ms. Diana ConradChief People OfficerMr. Philip C. ThomsonPresident of Global AffairsMore ExecutivesKey CompetitorsAstraZenecaLON:AZNHaleonLON:HLNDechra PharmaceuticalsLON:DPHSmith & NephewLON:SNConvaTec GroupLON:CTECView All CompetitorsInsidersEmma WalmsleySold 139,792 sharesTotal: £231.78 M ($1,658.00/share)Emma WalmsleyBought 8 shares on 2/9/2024Total: £13,296.00 ($1,662.00/share)Julie BrownBought 19,360 shares on 2/1/2024Total: £30.65 M ($1,583.00/share)Urs RohnerBought 478 shares on 12/20/2023Total: £693,100.00 ($1,450.00/share)Hal BarronBought 219 shares on 9/20/2023Total: £832,857.00 ($3,803.00/share)View All Insider Transactions Should I Buy GSK Stock? GSK Pros and Cons Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of GSK was last updated on Sunday, March 17, 2024 at 11:29 PM. Pros Here are some ways that investors could benefit from investing in GSK plc: GSK plc has shown consistent growth in institutional investments, indicating confidence from major financial entities like Anchor Investment Management LLC and Mercer Global Advisors Inc. ADV. Recent stock performance has been stable with a market cap of $88.80 billion, a price-to-earnings ratio of 14.33, and a beta of 0.64, providing a solid foundation for investment. GSK's quarterly earnings data revealed a net margin of 16.24% and a return on equity of 51.45%, showcasing strong financial health and profitability. Analysts predict a positive outlook for GSK plc with an expected earnings per share of 4.08 for the current fiscal year, indicating potential growth and value for investors. With a diverse portfolio and a history of innovation in the pharmaceutical industry, GSK plc offers long-term growth opportunities for investors seeking stability and potential returns. Cons Investors should be bearish about investing in GSK plc for these reasons: Despite positive institutional investments, GSK plc's stock has experienced a 1.0% decline recently, signaling potential short-term volatility or market challenges. The debt-to-equity ratio of 1.19 may raise concerns about the company's leverage and financial risk, impacting investor confidence in GSK's stability. The PEG ratio of 1.95 suggests that the stock may be slightly overvalued relative to its earnings growth potential, potentially limiting short-term gains for investors. GSK's stock price has been fluctuating around $43.14, indicating a level of uncertainty in the market and potential challenges in sustaining growth momentum. While GSK plc has a strong history, the competitive landscape in the pharmaceutical industry and regulatory uncertainties could pose risks to future growth and profitability for investors. GSK Stock Analysis - Frequently Asked Questions Should I buy or sell GSK stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares. View GSK analyst ratings or view top-rated stocks. What is GSK's stock price target for 2024? 7 equities research analysts have issued 12 month target prices for GSK's shares. Their GSK share price targets range from GBX 1,300 to GBX 1,950. On average, they anticipate the company's stock price to reach GBX 1,658.75 in the next twelve months. This suggests that the stock has a possible downside of 0.1%. View analysts price targets for GSK or view top-rated stocks among Wall Street analysts. How have GSK shares performed in 2024? GSK's stock was trading at GBX 1,450.20 at the beginning of 2024. Since then, GSK shares have increased by 14.5% and is now trading at GBX 1,660.80. View the best growth stocks for 2024 here. How were GSK's earnings last quarter? GSK plc (LON:GSK) issued its earnings results on Wednesday, July, 29th. The company reported $56.90 earnings per share (EPS) for the quarter. GSK had a trailing twelve-month return on equity of 46.38% and a net margin of 16.25%. How often does GSK pay dividends? What is the dividend yield for GSK? GSK declared a dividend on Wednesday, January 31st. Investors of record on Thursday, February 22nd will be paid a dividend of GBX 16 per share on Thursday, April 11th. This represents a yield of 1.04%. The ex-dividend date is Thursday, February 22nd. This is an increase from the stock's previous dividend of GBX 14. The official announcement can be accessed at this link. Read our dividend analysis for GSK. Is GSK a good dividend stock? GSK (LON:GSK) pays an annual dividend of GBX 64 per share and currently has a dividend yield of 3.83%. The dividend payout ratio is 5,333.33%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for GSK. What other stocks do shareholders of GSK own? Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AstraZeneca (AZN), General Electric (GE), Royal Dutch Shell (RDSB), Vodafone Group Public (VOD), Intel (INTC), NVIDIA (NVDA), Johnson & Johnson (JNJ), AT&T (T), Barclays (BARC) and Gilead Sciences (GILD). How do I buy shares of GSK? Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:GSK) was last updated on 3/19/2024 by MarketBeat.com Staff From Our Partners8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportThey said crypto was dead. It went up 100X.InvestorPlaceMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThe world’s greatest investmentPorter & CompanyStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.